AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) saw an uptick in trading volume on Friday . 2,293,301 shares were traded during trading, an increase of 111% from the previous session’s volume of 1,088,499 shares.The stock last traded at $14.45 and had previously closed at $14.45.
A number of brokerages have recently weighed in on AMAG. Cantor Fitzgerald restated a “hold” rating and set a $21.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, September 28th. B. Riley began coverage on AMAG Pharmaceuticals in a research note on Thursday, December 7th. They set a “neutral” rating and a $16.00 price target on the stock. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Tuesday, October 17th. Morgan Stanley dropped their price target on AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday, November 3rd. Finally, Zacks Investment Research upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a research note on Wednesday, October 4th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $23.38.
The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.48 and a current ratio of 1.59.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
What are top analysts saying about AMAG Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AMAG Pharmaceuticals and related companies.